4 products found
Gesynta Pharma AB Products
-
Pipeline
-
Gesynta Pharma - Model GS-248 - Advanced Drug Candidate
GS-248 is Gesynta Pharma’s most advanced drug candidate, currently in clinical development as a potential treatment of systemic sclerosis. Recent clinical phase I data in healthy individuals show that GS-248 potently inhibits the production of PGE2 in a tolerable and safe manner, while increasing the observed levels of protective and vasodilatory prostacyclin by two to three times. The study data also show that a once-daily oral dose is sufficient ...
-
Gesynta Pharma - Model GS-073 - Drug Candidate
Gesynta Pharma’s drug candidate GS-073 is expected to enter clinical phase I in 2022. It is currently in the final stages of preclinical development. This project will be addressing an indication with high unmet need, which is separate from systemic ...
-
Gesynta Pharma - Model GS-659 - Drug Candidate
The drug candidate GS-659, which is sprung from Gesynta Pharma’s drug development platform, is currently in preclinical development phase. Project updates will be announced in due ...
-
Therapeutic Areas
-
Model mPGES-1 - Microsomal Prostaglandin E Synthase
Microsomal prostaglandin E synthase (mPGES-1) is an enzyme generally present at low levels in the human body. It stimulates production of prostaglandin E2 (PGE2), a potent biological messenger that has a pronounced impact on inflammation. During inflammation the levels of mPGES-1 are upregulated, causing excessive levels of PGE2, which drive the inflammatory ...